StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) company profile

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.84−0.35 (-8.35%)

Close on Nov 17, 2026Market cap $696.49MP/E –Yield –

About Prime Medicine

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a biotechnology enterprise that develops genetic medicines using prime editing technology to correct pathogenic mutations without generating double-stranded DNA breaks. Its development pipeline encompasses wholly owned in vivo therapies for genetic liver and lung conditions as well as partnered ex vivo cell therapies. Key product candidates include PM577 for Wilson disease, PM647 for alpha-1 antitrypsin deficiency, an airway program for cystic fibrosis, and PM359 for chronic granulomatous disease. Its target beneficiaries are patients with severe genetic disorders, while its commercial counterparties and collaborators include biopharmaceutical corporations such as Bristol-Myers Squibb and non-profit organizations like the Cystic Fibrosis Foundation.

Regarding scale and geography, the provided text does not disclose the location of the company's corporate headquarters or its facility counts. The entity maintains research, manufacturing, and quality systems supporting preclinical and early-stage clinical operations. Its operations encompass worldwide intellectual property licenses and global commercial agreements, alongside regulatory engagement with authorities in the United States.

Summary of the business section of Prime Medicine's latest annual report, written by StockData.

Company profile

Company

Legal name
Prime Medicine, Inc.
Headquarters
Cambridge, MA
Address
60 First St. 02141
Phone
(617) 465-0013
Employees
146, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
PRME
Exchange
Nasdaq
IPO date
Oct 21, 2022
Shares outstanding
181M, Jul 31, 2026
Public float
$238.76M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1894562
CUSIP
74168J101
ISIN
US74168J1016
FIGI
BBG011RT3R55
Share class FIGI
BBG011RT3R64
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Allan ReineChief Executive Officer, Director125,000
Keith Michael GottesdienerSee Remarks, Director4,361,078
Svetlana Ni MakhniChief Financial Officer–
Carman AlensonSee Remarks–
Ann L. LeeChief Technical Officer100,000
Richard BrudnickChief Business Officer20,000
Meredith GoldwasserSVP, Strategy & Corporate Ops.176,917
Jeremy DuffieldChief Scientific Officer965,001
Wendy ChungDirector–
Robert NelsenDirector18,502,974
Kaye I. Foster-CheekDirector–
David P. SchenkeinDirector–
Michael Aaron KellyDirector–
Thomas CahillDirector5,305,679
Jeffrey D. MarrazzoDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Allan Reine, M.D.
Chief Executive Officer
$606.21K$2.83M$402.00K$57.18K$3.89M-16%
Keith Gottesdiener, M.D.
Former Chief Executive Officer
$259.57K$1.19M–$762.40K$2.21M-2%
Ann Lee, Ph.D.
Chief Technical Officer
$505.38K$790.08K$243.96K$10.71K$1.55M–
Jeremy Duffield, M.D., Ph.D., FRCP
Former Chief Scientific Officer
$268.27K$668.60K–$380.93K$1.32M-30%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 21, 2022
Offer price
$17.00
Securities offered
10,294,118
Gross proceeds
$175.00M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 19, 2023

“The initial public offering price of our common stock is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 146 full-time employees, of whom 63 have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?